利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

43 条记录 (耗时 0.044 秒)

    Enterohemorrhagic escherichia coli vaccine
    1.
    发明专利
    Enterohemorrhagic escherichia coli vaccine 审中-公开
    ENTEROHEMORRHAGIC ESCHERICHIA COLI VACCINE

    公开(公告)号：JP2013151499A

    公开(公告)日：2013-08-08

    申请号：JP2013028877

    申请日：2013-02-18

    申请人： Univ Of Saskatchewan ,  ユニバーシティー オブ サスカチェワン ,  Univ Of British Columbia ,  ザ ユニバーシティー オブ ブリティッシュ コロンビア

    发明人： FINLAY BRETT ,  POTTER ANDREW A

    IPC分类号： A61K39/108 ,  A61K35/74 ,  A61K39/02 ,  A61K39/39 ,  A61P31/00 ,  A61P31/04 ,  C07K14/245 ,  C12N1/20

    CPC分类号： A61K39/0258 ,  A61K2039/55566 ,  C07K14/245

    摘要： PROBLEM TO BE SOLVED: To provide a composition that stimulates an immune response to secretory enterohemorrhagic escherichia coli (EHEC) antigen, and a method therefor.SOLUTION: Provided is a vaccine composition is characterized by containing supernatant of enterohemorrhagic escherichia (EHEC) cell culture solution and immunoadjuvant, wherein the supernatant of the EHEC cell culture solution contains a mixture of antigen secreted by type III secretion system. The immunoadjuvant contains at least one selected from a group consisting of an emulsifier, muramyl dipeptide, water-soluble adjuvant, chitosan-based adjuvant, saponin, oil, lipopolysaccharide, bacterial cell wall extract, bacterial DNA, acid-fast bacterial cell wall complex, synthetic oligonucleotide, and aliphatic nitrogenous base. The subject of the vaccine composition is a mammal, especially a ruminant such as a bovine and a sheep.

    摘要翻译： 要解决的问题：提供刺激分泌性肠出血性大肠杆菌（EHEC）抗原的免疫应答的组合物及其方法。解决方案：提供一种疫苗组合物，其特征在于含有出血性埃希氏菌（EHEC）细胞培养液 和免疫佐剂，其中EHEC细胞培养液的上清液含有由III型分泌系统分泌的抗原的混合物。 免疫佐剂含有选自乳化剂，胞壁酰二肽，水溶性佐剂，脱乙酰壳多糖佐剂，皂苷，油，脂多糖，细菌细胞壁提取物，细菌DNA，耐酸菌细胞壁复合物中的至少一种， 合成寡核苷酸和脂肪族含氮碱基。 疫苗组合物的主题是哺乳动物，特别是反刍动物如牛和绵羊。

    Method for preparation of lipid-encapsulated therapeutic agent
    2.
    发明专利
    Method for preparation of lipid-encapsulated therapeutic agent 审中-公开
    脂质包埋治疗剂的制备方法

    公开(公告)号：JP2011225618A

    公开(公告)日：2011-11-10

    申请号：JP2011172656

    申请日：2011-08-08

    申请人： Univ Of British Columbia ,  ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア

    发明人： MAURER NORBERT ,  WONG KIM F ,  CULLIS PIETER R

    IPC分类号： A61J3/07 ,  A61K31/711 ,  A61K9/127 ,  A61K9/133 ,  A61K31/7125 ,  A61K45/00 ,  A61K47/10 ,  A61K47/12 ,  A61K47/16 ,  A61K47/18 ,  A61K47/24 ,  A61K47/28 ,  A61K47/34 ,  A61K47/48 ,  A61K48/00

    CPC分类号： A61K9/1278 ,  A61K9/1272 ,  A61K9/1277

    摘要： PROBLEM TO BE SOLVED: To generate fully lipid-encapsulated therapeutic agent particles.SOLUTION: A charged lipid which has a charge which is opposite to the charge of the charged therapeutic agent and a modified lipid having a steric barrier moiety for control of aggregation are formed. The lipid vesicles are prepared by combining a lipid composition containing preformed lipid vesicles, a charged therapeutic agent, and a destabilizing agent to form a mixture of preformed vesicles and therapeutic agent in a destabilizing solvent. The destabilizing solvent is effective to destabilize the membrane of the preformed lipid vesicles without disrupting the vesicles. The resulting mixture is incubated for a period of time sufficient to allow the encapsulation of the therapeutic agent within the preformed lipid vesicles. The destabilizing agent is then removed to yield fully lipid-encapsulated therapeutic agent particles.

    摘要翻译： 要解决的问题：产生完全脂质包封的治疗剂颗粒。 解决方案：形成具有与带电治疗剂的电荷相反的电荷的带电脂质和具有用于控制聚集的空间屏障部分的改性脂质。 通过将含有预先形成的脂质囊泡的脂质组合物，带电的治疗剂和去稳定剂组合以在去稳定溶剂中形成预先形成的囊泡和治疗剂的混合物来制备脂质囊泡。 不稳定溶剂有效地使预先形成的脂质囊泡的膜不稳定而不破坏囊泡。 将所得混合物温育足以允许将预处理的脂质囊泡中的治疗剂包封的时间。 然后去除去稳定剂以产生完全脂质包封的治疗剂颗粒。 版权所有（C）2012，JPO＆INPIT

    Hp90: host membrane receptor for pathogenic bacteria, encoded by bacterial tir gene
    4.
    发明专利
    Hp90: host membrane receptor for pathogenic bacteria, encoded by bacterial tir gene 审中-公开
    HP90：细菌性TIR基因编码的致病细菌的宿主细胞膜受体

    公开(公告)号：JP2009173667A

    公开(公告)日：2009-08-06

    申请号：JP2009071999

    申请日：2009-03-24

    申请人： Univ Of British Columbia ,  ザ ユニバーシティー オブ ブリティッシュ コロンビア

    发明人： FINLAY B BRETT ,  KENNY BRENDAN ,  DEVINNEY REBEKAH ,  STEIN MARCUS

    IPC分类号： A61K38/00 ,  G01N33/53 ,  A61K31/7088 ,  A61K39/00 ,  A61K48/00 ,  A61P1/00 ,  A61P31/04 ,  A61P37/04 ,  C07K14/24 ,  C07K14/245 ,  C07K16/12 ,  C12N5/10 ,  C12N15/09 ,  C12N15/31 ,  C12P21/02 ,  C12P21/08 ,  C12Q1/68 ,  C12R1/19

    CPC分类号： C07K14/24 ,  A61K39/00 ,  C07K2319/02

    摘要： PROBLEM TO BE SOLVED: To provide a pharmaceutical composition for diseases caused by infections of enteropathogenic E. coli (EPEC), enterohemorrhagic E. coli (EHEC) and the like.
    SOLUTION: Use of one of following items is provided: (i) a translocated intimin receptor polypeptide including a specific amino acid sequence or a substantially the same amino acid sequence, (ii) a polypeptide (i) nucleating actin and activating signal transmission pathways in host cells, (iii) a polypeptide (i) specifically binding to a Tir-specific antibody, (iv) a polypeptide (i) inducing immune response to EHEC in a host, (v) (a) a polynucleotide containing a specific nucleic acid sequence, (b) a polynucleotide described in (a) in which T is U, (c) a polynucleotide containing a nucleic acid sequence complementary to (a) or (b), or (d) a polynucleotide encoding a polypeptide containing a specific amino acid sequence, and (vi) a vector containing a polynucleotide (v).
    COPYRIGHT: (C)2009,JPO&INPIT

    摘要翻译： 要解决的问题：提供由肠致病性大肠杆菌（EPEC），肠出血性大肠杆菌（EHEC）等的感染引起的疾病的药物组合物。 提供了以下项目之一的用途：（i）包含特定氨基酸序列或基本上相同氨基酸序列的易位的肠粘膜受体多肽，（ii）多核苷酸（i）成核肌动蛋白和激活信号 宿主细胞中的传递途径，（iii）特异性结合Tir特异性抗体的多肽（i），（iv）多肽（i）诱导宿主中EHEC的免疫应答，（v）（a）含有 特异性核酸序列，（b）（a）中描述的多核苷酸，其中T是U，（c）含有与（a）或（b）互补的核酸序列的多核苷酸，或（d）编码多肽的多核苷酸 含有特定氨基酸序列，和（vi）含有多核苷酸（v）的载体。 版权所有（C）2009，JPO＆INPIT

    RNAi PROBE TARGETING CANCER-RELATED PROTEIN
    8.
    发明专利
    RNAi PROBE TARGETING CANCER-RELATED PROTEIN 审中-公开
    RNAi检测癌基因相关蛋白

    公开(公告)号：JP2013150624A

    公开(公告)日：2013-08-08

    申请号：JP2013067754

    申请日：2013-03-28

    申请人： Univ Of British Columbia ,  ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア

    发明人： JANSEN BURKHARD ,  GLEAVE MARTIN E ,  SIGNAEVSKY MAXIM ,  BERALDI ELIANA ,  TROUGAKOS IOANNIS P ,  GONOS EFSTATJIOS S

    IPC分类号： C12N15/113 ,  A61K31/712 ,  A61K31/713 ,  A61K38/00 ,  A61K48/00 ,  A61P35/00 ,  C12N15/00 ,  C12N15/09

    CPC分类号： C12N15/113 ,  A61K31/712 ,  A61K38/00 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3525

    摘要： PROBLEM TO BE SOLVED: To provide use of RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma and in the treatment of Alzheimer's disease, and a method of treating such diseases through the administration of RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.SOLUTION: RNAi sequences are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, undifferentiated large cell lymphoma and melanoma and in the treatment of Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and IGFBP-5 simultaneously, Mitf, and B-raf.

    摘要翻译： 要解决的问题：提供RNAi序列用于治疗各种类型的癌症，包括前列腺癌，肉瘤如骨肉瘤，肾细胞癌，乳腺癌，膀胱癌，肺癌，结肠癌，卵巢癌，间变性大 细胞淋巴瘤和黑素瘤以及阿尔茨海默病的治疗，以及通过向个体（包括需要这种治疗的个体）施用具有RNAi活性的RNA分子来治疗这些疾病的方法。解决方案：RNAi序列可用作治疗剂 在治疗各种类型的癌症中，包括前列腺癌，肉瘤如骨肉瘤，肾细胞癌，乳腺癌，膀胱癌，肺癌，结肠癌，卵巢癌，未分化大细胞淋巴瘤和黑素瘤，以及治疗阿尔茨海默病 。 这些序列同时靶向clusterin，IGFBP-5，IGFBP-2，IGFBP-2和IGFBP-5，Mitf和B-raf。